Granulome central à cellules géantes de l’enfant : présentation des différentes options thérapeutiques
| Autor: | M. Longeac, N. Pham Dang, M. Picard, Isabelle Barthélémy, Laurent Devoize |
|---|---|
| Přispěvatelé: | Neuro-Dol (Neuro-Dol), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA) |
| Rok vydání: | 2016 |
| Předmět: |
MESH: Remission Induction
medicine.medical_specialty Triamcinolone acetonide Granuloma giant cell [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery Benign tumor Calcitonine 03 medical and health sciences MESH: Mandibular Diseases 0302 clinical medicine Interferon MESH: Child medicine MESH: Interferons Corticothérapie MESH: Alendronate MESH: Humans Alendronate MESH: Calcitonin MESH: Denosumab Tumor size business.industry 030206 dentistry General Medicine MESH: Granuloma Giant Cell medicine.disease Surgery Surgical morbidity Granulome central à cellules géantes Denosumab MESH: Orthognathic Surgery Otorhinolaryngology Tumor progression 030220 oncology & carcinogenesis Steroids Oral Surgery MESH: Glucocorticoids business Central giant-cell granuloma medicine.drug |
| Zdroj: | Revue de Stomatologie, de Chirurgie Maxillo-faciale et de Chirurgie Orale Revue de Stomatologie, de Chirurgie Maxillo-faciale et de Chirurgie Orale, Société Française de Stomatologie Chirurgie Maxillo-faciale et de Chirurgie Orale (SFSCMFCO) / Elsevier, 2016, 117 (3), pp.142-146. ⟨10.1016/j.revsto.2016.01.007⟩ |
| ISSN: | 2213-6533 |
| Popis: | International audience; Central giant cell granuloma (CGCG) is a benign tumor that may be subdivided in a non-aggressive form and an aggressive form. In aggressive forms, tumor size and high recurrence risk need large surgical resections. In order to minimize surgical morbidity, especially in children, medical treatments acting on the tumor proliferation are currently being assessed: steroids (triamcinolone), anti-osteoclastic drugs (calcitonine, alendronate, denosumab), anti-angiogenic drugs (interferon α). However to date, there is no evidence for any superiority of medical over surgical treatment. Complete response is rarely obtained and additional surgery is often necessary to remove the tumor in case of tumor progression, to remove a remnant or to remodel bone. Moreover, these drugs have frequent local or systemic side effects such as osteonecrosis and growth deficiencies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect